Table 3.
Main characteristics of cell preparation and the cellular product applied
| Case number | Amount of bone marrow obtained (mL) | Complications during bone marrow harvest | Number of MSC obtained after expansion | Number of MSC applied in suture line | Surgical procedure | Surgical approach | Complications during treatment |
|---|---|---|---|---|---|---|---|
| 1 | 90 | No | 60 million | 60 million | Left upper lobectomy | Thoracotomy | No |
| 2 | 90 | No | 104 million | 60 million | Segmentectomy (Left S1-3) | Thoracotomy | No |
| 3 | 82 | No | 142 million | 36 million | Middle lobectomy | VATS | No |
| 4 | 95 | No | 255 million | 60 million | Right upper lobectomy | VATS | No |
| 5 | 90 | No | Insufficient expansion | Not applied | Segmentectomy (Left S1-3 and S6) | Thoracotomy | – |
| 6 | 80 | No | 120 million | 60 million | Left upper lobectomy | VATS | No |
| 7 | 90 | No | 100 million | 60 million | Right upper lobectomy + wedge middle lobe + wedge S6 | VATS | No |
| 8 | 90 | No | 45 million | 35 million | Wedge right upper lobe + wedge middle lobe + mechanical and chemical pleurodesis | VATS | No |
VATS video-assisted thoracic surgery